PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to journals

Source

Neurology

2 developments in the corpus

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 30, 2026 · JOURNAL ARTICLE

Multifactorial Contributors to Dose Limiting and Post-Treatment Neurologic Toxicity During Chemotherapy Treatment

Neurology

BACKGROUND AND OBJECTIVES: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a complex and dose-limiting toxicity of cancer treatment leading to increased disability and redu

AUG 5, 2026 · JOURNAL ARTICLE

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.

Neurology

Retrospective eligibility analysis demonstrating that 70–85% of biomarker-confirmed atypical AD patients would be ineligible for anti-amyloid therapies, primarily due to cognitive thresholds misaligned with disease severity.

Important Confirmatory EvidenceNick Corriveau-Lecavalier Vijay K Ramanan Biomarkers

Reported

Sample size184

PCA subgroup98 (53.3%)

lvPPA subgroup42 (22.8%)

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support